Work

Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

Year: 2022

Type: article

Source: Journal of Hepatology

DOI: 10.1016/s0168-8278(22)00440-8

Authors: Rohit Loomba, Manal F. Abdelmalek, Matthew Armstrong, Maximilian Jara, Mette Kjaer, Niels Krarup, Eric Lawitz, Vlad Ratziu, Arun Sanyal, Jörn Schattenberg, Philip N. Newsome

Institutions: University of California San Diego, Duke University, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Novo Nordisk (Denmark), The University of Texas at San Antonio Health Science Center, Texas Liver Institute, Sorbonne Université, Pitié-Salpêtrière Hospital, Virginia Commonwealth University, University Medical Center of the Johannes Gutenberg University Mainz

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4283808223

FWCI: 1.994

Cites:

Cited by: 11

Related to: 10